Convelo Therapeutics

Convelo Therapeutics

Overview

Convelo Therapeutics is a clinical-stage biotechnology company developing novel therapeutics that promote remyelination and synaptic repair in neurological diseases. Founded based on discoveries from Case Western Reserve University, the company targets the molecular mechanisms that drive oligodendrocyte dysfunction and synaptic loss in multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis [@convelo2024].

Convelo Therapeutics

Overview

Convelo Therapeutics is a clinical-stage biotechnology company developing novel therapeutics that promote remyelination and synaptic repair in neurological diseases. Founded based on discoveries from Case Western Reserve University, the company targets the molecular mechanisms that drive oligodendrocyte dysfunction and synaptic loss in multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis [@convelo2024].

The company's platform addresses two interconnected pathological hallmarks of neurodegeneration: myelin degeneration and synaptic dysfunction. By targeting potassium channels on oligodendrocyte precursor cells (OPCs) and synaptic repair pathways, Convelo aims to restore the structural and functional integrity of the nervous system.

Company Profile

| Attribute | Details |
|-----------|---------|
| Founded | 2017 |
| Headquarters | Cleveland, Ohio, USA |
| Focus | Remyelination, synaptic repair |
| Stage | Preclinical to Phase 1 |
| Founders | Dr. Edward Feldman's group, Case Western Reserve University |
| Investors | Not disclosed |

Technology Platform

OPC Potassium Channel Modulation

Convelo's lead mechanism targets voltage-gated potassium channels on oligodendrocyte precursor cells. OPCs express specific potassium channels (including Kir4.1 and Kv1.x family members) that regulate their membrane potential and differentiation capacity. In disease states, these channels become dysregulated, preventing OPCs from differentiating into mature, myelinating oligodendrocytes [@chen2020].

Mechanism:
The company's small molecule potassium channel blockers promote OPC differentiation through several pathways:

Preclinical Data:
In cuprizone-induced demyelination models, Convelo's compounds increased the number of mature oligodendrocytes and improved myelin integrity as assessed by electron microscopy and behavioral outcomes. The approach is particularly compelling because it works through the native differentiation pathway rather than imposing an artificial state.

Synaptic Repair Mechanisms

Beyond remyelination, Convelo is developing approaches that directly address synaptic dysfunction in neurodegenerative diseases. These programs recognize that:

• Synaptic loss correlates strongly with clinical disability in PD, AD, and ALS
• Dendritic spine density decreases in medium spiny neurons and cortical pyramidal neurons in these diseases
• Enhancing synaptic protein expression and spine formation may preserve cognitive and motor function

• Synaptic scaffolding proteins (PSD-95, Homer1)
• Presynaptic release machinery
• Dendritic spine actin dynamics

Pipeline

CVL-354

CVL-354 is Convelo's lead clinical program, a potassium channel blocker that promotes oligodendrocyte differentiation and remyelination. The compound is being evaluated in Phase 1 clinical trials for multiple sclerosis, with parallel preclinical development for [Parkinson's disease](/diseases/parkinsons-disease).

• Mechanism: Potassium channel blockade on OPCs → promoted differentiation → remyelination
• Indication: Multiple sclerosis (primary), Parkinson's disease (secondary)
• Stage: Phase 1 (MS), preclinical (PD)
• Route: Oral small molecule

• Safety and tolerability at doses achieving target engagement
• CSF biomarker changes consistent with OPC differentiation
• Good pharmacokinetic properties for a CNS-targeted therapy

CVL-231

CVL-231 is a next-generation remyelination compound in preclinical development, optimized for enhanced CNS penetration and improved tolerability.

• Mechanism: Enhanced potassium channel targeting with improved selectivity
• Indication: Multiple sclerosis
• Stage: Preclinical (IND-enabling studies)

Synaptic Repair Discovery Programs

Convelo has active discovery-stage programs targeting synaptic repair mechanisms for [Parkinson's disease](/diseases/parkinsons-disease) and ALS:

• Program SR-1: Small molecule approach to enhance synaptic protein expression
• Program SR-2: Target identification for dendritic spine stabilization
• Stage: Discovery

Science

Oligodendrocyte Biology

Oligodendrocytes are the myelinating cells of the central nervous system, producing the myelin sheath that enables rapid saltatory conduction and provides metabolic support to axons. In Parkinson's disease and other neurodegenerative conditions, oligodendrocyte dysfunction contributes to circuit failure independent of primary neuronal loss [@feldman2019].

Key Concepts:

• OPCs constitute 5-10% of cells in adult human brain white matter
• OPCs continuously survey the CNS for demyelinated axons
• In disease states, inflammatory cytokines (IFN-γ, TNF-α) inhibit OPC differentiation
• Potassium channel dysfunction is a common mechanism of OPC arrest

• Lactate supply via monocarboxylate transporters
• Local glucose regulation
• Axonal transport support
• Protection from oxidative stress

Synaptic Dysfunction in PD

Synaptic loss in Parkinson's disease occurs through multiple mechanisms that Convelo's programs aim to address:

• Dopaminergic denervation: Loss of trophic support from substantia nigra neurons
• Alpha-synuclein toxicity: Aggregation disrupts synaptic vesicle function and protein trafficking
• Neuroinflammation: Microglial activation and complement-mediated synapse elimination
• Oxidative stress: Mitochondrial dysfunction at synapses

Comparison to Other Companies

| Company | Approach | Stage | PD Relevance |
|---------|----------|-------|-------------|
| Convelo | K+ channel / remyelination | Phase 1 | Addresses nigrostriatal myelin |
| Rodin | HDAC6 inhibition | Phase 1-2 | Microtubule / synaptic transport |
| Synaptic Therapeutics | Sigma-2 modulation | Preclinical | Direct synaptic protection |
| Lundbeck | PDE4B inhibition | Preclinical | Synaptic plasticity enhancement |
| AbbVie | TREM2 agonists | Phase 1-2 | Microglial synaptic support |

Cross-References

• [Parkinson's Disease Synaptic Repair and Preservation Companies](/companies/pd-synaptic-repair-preservation-companies)
• [Remyelination Therapies](/therapeutics/remyelination-therapies)
• [Oligodendrocyte Function in Neurodegeneration](/cell-types/oligodendrocytes)
• [Myelin Dysfunction in Parkinson's Disease](/mechanisms/myelin-dysfunction-pd)
• [Synaptic Plasticity Therapeutics for Parkinson's Disease](/therapeutics/synaptic-plasticity-therapeutics-pd)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

See Also

• [Alpha-Synuclein Pathogenesis](/mechanisms/alpha-synuclein-pathogenesis)
• [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
• [Multiple Sclerosis Treatments](/therapeutics/multiple-sclerosis-treatments)

External Links

• [Convelo Therapeutics](https://www.convelotx.com)
• [Case Western Reserve University Research](https://case.edu/medicine)

References